Open AccessSynthesis, anticancer and FGFR1 inhibitory activity of isoindolo[2,1-a][1,2,4]triazino[2,3-c]quinazoline derivatives
Author(s) -
О. Yu. Voskoboynik,
Sergiy A. Starosyla,
M. V. Protopopo,
H. P. Volynets,
S. V. Shyshkina,
S. M. Yarmoliuk,
С. И. Коваленко
Publication year - 2016
Publication title -
medična ì klìnìčna himiâ
Language(s) - English
Resource type - Journals
eISSN - 2414-9934
pISSN - 2410-681X
DOI - 10.11603/mcch.2410-681x.2016.v0.i1.6123
Subject(s) - chemistry , quinazoline , hydrogen bond , benzoic acid , inhibitory postsynaptic potential , stereochemistry , combinatorial chemistry , biochemistry , organic chemistry , molecule , neuroscience , biology
Presented manuscript describes the synthesis, antitumor and FGFR1 inhibitory activity of novel isoindolo[2,1-a][1,2,4]triazino[2,3-c]quinazolines. It was shown that mentioned above substances may be prepared by interactionof 3-(2-amino-3-R2-5-R3-phenyl)-6-R1-1,2,4-triazin-5(2H)-ones with 2-formylbenzoic and 6-formyl-2,3-dimethoxybenzoic (opianic) acids in acetic acid. It was shown that proper 2-(2-oxo-3-R-6,7-dihydro-2H-[1,2,4]triazino[2,3-c]quinazolin-6-yl)benzoic acids (or corresponded dimethoxysubstituted analogues) may be considered as intermediates of thereaction. Spectral properties of synthesized compounds were studied, it was shown that protons in position 8 wereobserved at low field as result of the presence of hydrogen bond between hydrogen at position 8 and oxygen atposition 10. The anticancer assay data allowed to identify synthesized compounds as promising antitumor agents.The FGFR1 inhibitory activity of synthesized compounds was detected and docking study aimed to the evaluationof mentioned action was conducted.